eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
10.10
+0.08 (0.80%)
Jul 10, 2025, 4:00 PM - Market open
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
31
Market Cap
84.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEXOZ News
- 14 days ago - eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing - Accesswire
- 2 months ago - eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast - Accesswire
- 2 months ago - eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today - Accesswire
- 2 months ago - eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST - Accesswire
- 2 months ago - eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health - Accesswire
- 2 months ago - Bringing clarity and precision to the cell-free space by introducing exozymes - GlobeNewsWire
- 3 months ago - BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - GlobeNewsWire
- 3 months ago - eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewsWire